This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Fisher, M. Articles by Levine, P. H. Search for Related Content PubMed PubMed Citation Articles by Fisher, M. Articles by Levine, P. H.

Stroke, Vol 15, 813-816, Copyright © 1984 by American Heart Association

ARTICLES

Selective thromboxane inhibition: a new approach to antiplatelet therapy

M Fisher, B Weiner, IS Ockene, JS Hoogasian, AM Natale, JR Arsenault, MH Johnson and PH Levine

Antiplatelet drugs as exemplified by aspirin are used frequently to prevent stroke. Aspirin inhibits the formation of both the potent platelet aggregator, thromboxane A2 and the potent anti-aggregator, prostacyclin. Another approach to the inhibition of platelet aggregation might involve selective suppression of thromboxane formation. We report our experience in swine with UK-38,485, a drug which selectively inhibits thromboxane formation. The rationale and potential uses of UK-38,485 in the in vivo prevention of platelet aggregation and for the therapy of cerebrovascular disease are discussed.